Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome

Journal of Clinical Pathology

Volumn 61, Issue 5, 2008, Pages 623-626

  Beqaj, S H ^a   Lerner, A Martin ^b,d   Fitzgerald, J T ^c  

^a Pathgroup Labs   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; GENE PRODUCT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN P52; VIRUS CAPSID ANTIGEN;

ARTICLE; ASSAY; CHRONIC FATIGUE SYNDROME; COPALIS ASSAY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROLOGY; VIRUS DETECTION; VIRUS INFECTION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATIGUE SYNDROME, CHRONIC; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; VIRAL PROTEINS;

EID: 43549115898     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.050633     Document Type: Article

References (34)

1. Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med 1999;159:2129-37.
2. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988;108:387- 9.
3. Lerner AM, Beqaj SH, Deeter RG, et al. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo 2004;18:101-10.
4. 2 (UL44 and UL 57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo 2002;16:153-60.
5. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953- 9.
6. Lerner AM, Deeter RG, O'Neill W. Cardiac and virologic issues. In: Jason LA, Fennell PA, Taylor RR, eds. Handbook of chronic fatigue syndrome. Hoboken, NJ: John Wiley & Sons, 2003:304-30.
7. Lerner AM, Zervos M, Chang CH, et al. A small-randomized placebo controlled trial of the use of antiviral therapy for patients with the chronic fatigue syndrome. Clin Infect Dis 2001;32:1657-8.
8. Aitken C, Barrett-Muir W, Millar CT, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999;37:2804-7.
9. Tanabe K, Tokumoto T, Ishikawa N, et al. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997;64:1721-5.
10. Vornhagen R, Plachter B, Hinderer W, et al. Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens. J Clin Microbiol 1994;32:981-6.
11. Lazzarotto T, Dalla Casa BD, Campisi B, et al. Enzyme-linked immunoadsorbent assay for the detection of cytomegalovirus-IgM: comparison between eight commercial kits, immunofluorescence and immunoblotting. J Clin Lab Anal 1992;6:216-8.
12. Marsano L, Perrillo RP, Flye MW, et al. Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis 1990;161:454-61.
13. Ripalti A, Dal Monte P, Boccuni MC, et al. Prokaryotic expression of a large fragment of the most antigenic cytomegalovirus DNA binding protein (pp UL44) and its reactivity with human antibodies. J Virol Methods 1994;46:39-50.
14. Lerner AM, Beqaj SH, Deeter RG, et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs of Today 2002;38:549-61.
15. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3.
16. Lerner AM, Dworkin HJ, Sayyed T, et al. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-Barr virus and/or cytomegalovirus in patients with chronic fatigue syndrome. In Vivo 2004;18:417-24.
17. Griffiths PD, Grundy JE. Molecular biology and immunology of cytomegalovirus. Biochem J 1987;241:313-24.
18. Pedneault L, Robillard L, Harvey P, et al. Comparison of four enzyme immunoassays for the detection of cytomegalovirus IgG antibodies. Clin Diag Virol 1993;1:215-33.
19. Daiminger A, Boder U, Enders G, et al. An enzyme immunoassay using recombinant antigens for differentiation of primary from secondary or post CMV infections in pregnancy. J Clin Virol 1998;11:93-102.
20. Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 1984;81:3998-4002.
21. Lerner AM, Lawrie C, Dworkin HJ. Repetitively changing T-waves at 24-hr electrocardiographic monitors in patients with chronic fatigue syndrome. Left ventricular dysfunction in a cohort. Chest 1993;104:1417-21.
22. Lerner AM, Goldstein J Chang, et al. Cardiac involvement in patients with chronic fatigue syndrome as documented with Holter and biopsy data in Birmingham, MI 1991-1993. Infect Dis Clin Pract 1997;6:327-33.
23. Landini MP, Lazzaroto T, Maine GT, et al. Recombinant mono and poly antigens to detect cytomegalovirus specific immunoglobulin M in human sera by enzyme immunoassay. J Clin Microbiol 1995;33:2535-42.
24. Chee MS, Bankier AT, Beck S, et al. Analysis of the protein coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990;154:125-69.
25. van Zanten J, Harmsen MC, van der Giessen M, et al. Humoral immune response against cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins. Clin Diagn Lab Immunol 1995;2:214-8.
26. Landini MP. New approaches and perspectives in cytomegalovirus diagnosis. Prog Med Virol 1993;40:157-77.
27. Landini MP, Guan MX, Jahn G, et al. Large-scale screening of human sera with cytomegalovirus recombinant antigens. J Clin Microbiol 1990;28:1375-9.
28. Landini MP, Ripalti A, Sra K, et al. Human cytomegalovirus structural proteins: immune reaction against pp 150 synthetic peptides. J Clin Microbiol 1991;29:1868-72.
29. Landini MP, Lazzarotto T, Ripalti A, et al. Antibody response to recombinant lambda g+11 fusion proteins in cytomegalovirus infection. J Clin Microbiol 1989;27:2324-7.
30. Roizman B. The family herpesviridae: a brief introduction from In: Roizman B, Whitely RJ, Lopez C, eds. The human herpesvirses. New York: Raven Press, 1990:1-10.
31. Thorley-Lawson DA. EBV persistence and latent infection. In vivo. In: Robertson ES, ed. Epstein-Barr virus. Wymondham: Caister Academic Press, 2005:309-58.
32. Lerner AM, Zervos M, Dworkin HJ, et al. A unified theory of the cause of the chronic fatigue syndrome. Infect Dis Clin Pract 1997;6:239-43.
33. Lerner AM, Beqaj SH, Deeter RG, et al. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome, thirty-six month follow-up. In Vivo 2007;21:707-14.
34. Mocarski ES Jr. Cytomegalovirus biology and replication. In: Roizman B, Whitley RJ, Lopez C, eds. The human herpesviruses. New York: Raven Press, 173-226.